---
ID: P95
Title: Radiation Oncology Precision Planner
Registry: CLAI-OS Precision Engine (P-series)
License: Open documentation release (prompt body withheld for validation)
Version: 1.0.0
Author: Dr. Christabel Odeta — SAVANT FRAMEWORK · CLAI-OS · AEGIS-GLOBAL
Last Updated: 2026-10-12
---

# P95: Radiation Oncology Precision Planner

## Abstract

Conventional radiation planning optimizes geometry. P95 optimizes survivability by integrating tumor oxygenation, hematologic reserve, genomic repair competency, inflammatory state, and temporal anatomical change into a single adaptive radiation decision layer. The system treats radiation as a dynamic biological intervention whose efficacy depends on evolving tissue states, immune interactions, perfusion characteristics, repair kinetics, and systemic disease physiology.

> Prompt body: WITHHELD. This is an open documentation release — abstract, methodology, and merits — published so the design can be examined and validated.

## Methodology

**Design objectives**

- Multi-layer planning integrating diagnostic imaging (CT, MRI, PET-CT, functional MRI), molecular profiling (ATM, ATR, BRCA1/2, TP53, CHEK2, FANCA), physiologic profiling (hemoglobin, oxygenation, CRP, albumin), and temporal adaptation (weekly CBCT, deformable registration).
- AI-assisted segmentation validated against RTOG consensus atlases, with mandatory physician verification, contour uncertainty heatmapping, and automated TG-263 nomenclature enforcement.
- Radiobiological modeling (BED, EQD2, TCP, NTCP) with tumor-specific targets (for example NSCLC SBRT BED above 100 Gy, prostate hypofractionation exploiting low alpha/beta ratio) and normal tissue constraints (lung V20, mean heart dose, cord maximum 14 Gy single fraction, duodenal V35 below 5%).
- Adaptive radiation oncology with weekly replanning triggers (shift greater than 3 mm, volume change greater than 5%, cachexia, pleural effusion, ascites, weight change greater than 10%) and response-guided escalation for persistent PET avidity, hypoxic subvolume persistence, or ctDNA persistence.
- Sickle-cell disease radiation adaptation with exchange transfusion consideration, hypoxia-adjusted BED recalculation, pulmonary dose minimization, and acute chest syndrome prevention protocols.

**Methodological innovation**

- Genomic radiosensitivity integration: DNA repair deficiency detection (ATM, BRCA1/2, TP53, Fanconi pathway) triggers dose de-escalation, fractionation modification, expanded marrow sparing, and enhanced toxicity surveillance.
- Physiological precision compiler: BED recalculation from real-time hemoglobin, oxygenation indices, and inflammatory state rather than population-average assumptions.
- Sickle-cell-specific planning: baseline hemoglobin 6-8 g/dL, chronic hypoxia, microvascular occlusion, and inflammatory endothelial activation explicitly modeled in dose-effect relationships.

**Key performance indicators**

- Geometric targeting accuracy (Dice coefficient, Hausdorff distance)
- Adaptive replanning appropriateness
- Radiation-induced toxicity reduction in repair-deficient patients
- Tumor control probability improvement
- Sickle-cell-specific acute chest syndrome prevention rate
- Organ-at-risk sparing optimization

**Integration**

- Upstream: P91 (Genomic Variant Actionability Arbiter) for radiosensitivity variants; P93 (Immune Evasion & Microenvironment Profiler) for radiation-immune interaction modeling.
- Downstream: P96 (Surgical Oncology Margin & Morbidity Optimizer) for preoperative radiation sequencing; P108 (Rehabilitation & Survivorship Architect) for radiation late-effects monitoring.

## Merits

- Personalizes radiotherapy to genomic repair competency and real-time physiology rather than geometry alone.
- Aims to reduce radiation toxicity in repair-deficient and physiologically vulnerable patients.
- Anemia-adjusted oxygenation modeling and hypoxia-aware dose recalculation for hematologic comorbidity.
- Adaptive replanning responds to anatomical and biological change during a treatment course.
- Resource-aware radiation planning with explicit normal-tissue constraint governance.

## Guidance for Use

This document records the design intent and scientific rationale of P95 (Radiation Oncology Precision Planner) as published in the CLAI-OS Tier III (Savant Precision Engine, P91–P110) compendium. The executable prompt body is withheld; nothing in this file is sufficient to operate the module. The material is released openly so that the design can be examined, critiqued, and independently validated.

Appropriate use:

- Scientific review, replication design, and methodological critique by researchers and validation groups.
- Reference for integration planning across the P-series registry.
- Citation in scholarly or institutional work describing the CLAI-OS Precision Engine.

Limitations:

- This is not a medical device, a clinical decision-support product, or a standard of care. Nothing in this document may be used to direct diagnosis, treatment, dosing, or triage for any patient.
- Genomic and oncology statements reflect only the claims made in the source compendium; publication of this documentation does not constitute independent clinical validation.
- Dose targets and constraints cited above are the planning parameters stated in the source compendium; clinical dosing remains subject to institutional protocols and physician judgment.

---

C0 informational classification; confers no clinical, legal, financial, or safety authority.
